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Cancers are aggressive, evasive, and ruthless killers, claiming millions of 
lives every year. Cancers are heterogeneous and there is often no single, 
clearly defined problem as they harness and manipulate a multitude of 
fundamental mechanisms at the very essence of life. To investigate these 
mechanisms and vet potential interventive therapies, humanized mice offer a 
unique model as a prelude to the use of nanosecond pulse stimulation (NPS), a 
pulse power technology applying nanosecond duration, high electric field 
pulses, to ablate human tumors. Immunodeficient mouse strains, NSG and 
NSG-SGM3, were engrafted with human immune cells and human tumors, 
which would allow us to study the effects of NPS therapy on the human tumor 
and the human immune system, albeit not without trials and tribulations. Here 
we show that mice engrafted with human cord blood CD34+ hematopoietic 
stem cells (hCD34+ HSC) lack consistency in expansion and chimerism, or 
variety of immune cell types. Unfortunately, mice that developed the human 
immune system rejected the human tumors without treatment, while mice that 
rejected the immune system developed the human tumors. Therefore, we had 
mice with human immune systems and no tumor to treat, and mice with 
tumors to treat yet no immune system to study. In non-humanized mice, NPS 
induced complete tumor death in the patient derived mammary cancer 
xenograft (PDX) model, but not in the MDA-MB-231 VIM-RFP mammary 
cancer cell-derived xenograft (CDX) model. The absence of NPS elimination 
of the CDX is the only known NPS cancer failure and requires further study. 
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▪ Humanization rarely occurred
▪ GvHD also occurred 
▪ PDX tumors were often rejected
▪ PDX tumors were cleared with NPS
▪ CDX tumors did not regress with NPS
▪ Hu-mice that developed the human immune cells, rejected the PDX 
▪ Hu-mice that rejected the human immune cells, accepted the PDX
Fig.2. Representative analysis of HCB CD34+ stem cells pre-engraftment. The StemCell HCB CD34+ Stem 
Cell Isolation Kit was used for positive selection of HCB CD34+ HSC. After cryopreservation, flow cytometry 
was used to confirm the purity of the isolated cells prior to humanizing mice. Impure samples might include 
various types of mature immune cells which could inadvertently induce graft-versus-host disease (GvHD) and 
lead to premature mortality. 
Fig.3. Human PDX (A) and CDX (B) tumor volumes in HU-NSGM3 mice post-treatment with NPS. 
Tumors were monitored for development and treated with NPS approximately 16-20-weeks post-engraftment 
of HCB CD34+ HSC. (A) PDX tumors completely regressed after treatment; however, (B) CDX tumors 
continued to develop after treatment. The progression of the CDX tumor development was the first time NPS 
has been ineffective at inducing tumor death. 
Fig.4. Human CD45+ leukocyte 
expansion over time in HU-NSGM3 
mice. Blood was collected from HU-
NSGM3 mice over the anticipated 
engraftment timeframe. The first indication 
of humanization is by observing the 
percentage of  human lymphocytes, which 
are hCD45+ cells, in the blood. Here, you 
can see that over time, only two of the mice  
in this group developed human 
lymphocytes, while the others rejected the 
engrafted stem cells.
Fig.5.  Human lymphocyte populations in HU-NSGM3 mice after 
humanization. Over time, the engrafted HCB CD34+ HSC expand and 
differentiate into a variety of human immune cells, including B cells 
(hCD19+), T cells (hCD3+), myeloid cells (hCD33+), and HSC (hCD38+). 
However, adequate expansion rarely occurred, and data is shown for a single 
mouse. 
Onco-Hu Models: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics. The Jackson Laboratory; 2019.
Fig.1. Humanized mouse models. NSG or NSG-SGM3 mice were engrafted 
with HCB CD34+ HSC at 4-6-wks old. Mice were treated with sublethal 
irradiation 4-6-hrs prior to receiving HCB CD34+ stem cells via IP injection. 
The developing immune system was monitored via regular blood checks. 
After 10-12-wks, tumors were started in the mammary fat pad of hu-mice. 
The tumors were treated with NPS (1000, 100ns Blumlein line pulses at 
50kV/cm and 3Hz) 16-20-weeks post-HCB CD34+ HSC engraftment.
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